CA2958222A1 - Superior human papilloma virus antigens with superior immunological properties and vaccine containing it - Google Patents

Superior human papilloma virus antigens with superior immunological properties and vaccine containing it Download PDF

Info

Publication number
CA2958222A1
CA2958222A1 CA2958222A CA2958222A CA2958222A1 CA 2958222 A1 CA2958222 A1 CA 2958222A1 CA 2958222 A CA2958222 A CA 2958222A CA 2958222 A CA2958222 A CA 2958222A CA 2958222 A1 CA2958222 A1 CA 2958222A1
Authority
CA
Canada
Prior art keywords
hpv
vaccine
protein
human papilloma
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2958222A
Other languages
English (en)
French (fr)
Inventor
Gaurav Gupta
Viviana Giannino
Reinhard Glueck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of CA2958222A1 publication Critical patent/CA2958222A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA2958222A 2014-09-11 2015-09-11 Superior human papilloma virus antigens with superior immunological properties and vaccine containing it Abandoned CA2958222A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2905MU2014 2014-09-11
IN2905/MUM/2014 2014-09-11
PCT/IN2015/000355 WO2016038625A2 (en) 2014-09-11 2015-09-11 Superior human papilloma virus antigens with superior immunological properties and vaccine containing it

Publications (1)

Publication Number Publication Date
CA2958222A1 true CA2958222A1 (en) 2016-03-17

Family

ID=54843870

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2958222A Abandoned CA2958222A1 (en) 2014-09-11 2015-09-11 Superior human papilloma virus antigens with superior immunological properties and vaccine containing it

Country Status (10)

Country Link
EP (1) EP3191505A2 (pt)
JP (1) JP2017528137A (pt)
CN (1) CN107002085A (pt)
AR (1) AR101840A1 (pt)
AU (1) AU2015313756A1 (pt)
BR (1) BR112017004181A2 (pt)
CA (1) CA2958222A1 (pt)
EA (1) EA201790365A1 (pt)
MA (1) MA40624A (pt)
WO (1) WO2016038625A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104845985B (zh) * 2014-02-18 2020-02-07 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
BR112018007870A2 (pt) 2015-10-19 2019-01-15 Cadila Healthcare Ltd composição imunogênica, método para a preparação de uma composição imunogênica, composição farmacêutica, vacina, método para estimular uma resposta imune em um paciente
CN109750049B (zh) * 2017-11-07 2023-08-18 上海泽润生物科技有限公司 重组人乳头瘤病毒52亚型蛋白表达
JP2021502822A (ja) * 2017-11-14 2021-02-04 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． ｉｎ ｖｉｔｒｏ及びｉｎ ｖｉｖｏでの遺伝子送達のための非ヒトパピローマウイルス
BR102020006846A2 (pt) * 2020-04-03 2021-12-07 Imunoscan Engenharia Molecular Ltda Peptídeos sintéticos miméticos a proteína l1 do hpv, método de diagnóstico de hpv, sistema de diagnóstico de hpv, composição farmacêutica e uso dos mesmos no tratamento ou profilaxia do hpv

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501285A (ja) * 1995-11-15 2000-02-08 メルク エンド カンパニー インコーポレーテッド 合成ｈｐｖ１１ウイルス様粒子
DK0973546T3 (da) * 1997-04-08 2004-06-28 Merck & Co Inc Stabiliserede formuleringer med human papillomavirus
EP1700911B1 (en) * 1997-09-05 2016-04-06 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
WO2005123762A2 (en) * 2004-06-18 2005-12-29 Indian Immunologicals Ltd Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16
CN101487009B (zh) * 2008-01-15 2012-11-21 上海泽润生物科技有限公司 用毕赤酵母表达系统制备抗人乳头瘤病毒16型感染的疫苗的方法
WO2009076824A1 (zh) * 2007-11-23 2009-06-25 Shanghai Zerun Biotechnology Co., Ltd. 人乳头状瘤病毒主要衣壳蛋白l1基因及其用途
CN102159239A (zh) * 2008-07-31 2011-08-17 葛兰素史密斯克莱生物公司 针对hpv的疫苗
MX2011013566A (es) * 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
CN102154325B (zh) * 2011-01-01 2013-08-21 上海生物制品研究所有限责任公司 针对人乳头瘤状病毒的疫苗及其制法和用途
CA2835967A1 (en) * 2011-05-13 2012-11-22 Folia Biotech Inc. Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
ES2762230T3 (es) * 2011-06-24 2020-05-22 Merck Sharp & Dohme Formulaciones de vacuna contra el HPV que comprenden un adyuvante de aluminio y métodos de producción de las mismas
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CN103667319B (zh) * 2012-09-10 2017-09-26 同济大学 抗人乳头瘤病毒的三价疫苗及其制法和用途

Also Published As

Publication number Publication date
MA40624A (fr) 2016-03-17
CN107002085A (zh) 2017-08-01
EP3191505A2 (en) 2017-07-19
JP2017528137A (ja) 2017-09-28
AR101840A1 (es) 2017-01-18
WO2016038625A3 (en) 2016-04-28
EA201790365A1 (ru) 2017-07-31
AU2015313756A1 (en) 2017-03-09
BR112017004181A2 (pt) 2017-12-05
WO2016038625A2 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
US9428555B2 (en) Truncated L1 protein of Human Papillomavirus type 16
CA2958222A1 (en) Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
US9249193B2 (en) Truncated L1 protein of human papillomavirus type 33
US20120087937A1 (en) Novel compositions
KR20050002868A (ko) 인간 파필로마 바이러스의 바이러스 유사 입자
CZ336696A3 (en) Isolated and purified proteins of papillomavirus and process for preparing thereof
US7897155B2 (en) Method for producing yeast expressed HPV types 6 and 16 capsid proteins
PL183299B1 (pl) Izolowana i oczyszczona cząsteczka kwasu nukleinowego kodująca białko L1 ludzkiego wirusa brodawczaków typu 11, wektor ekspresyjny obejmujący tę cząsteczkę i kompozycja
EP2589604B1 (en) Truncated l1 protein of human papillomavirus type 52
KR101608121B1 (ko) 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물
US9034340B2 (en) Genes encoding major capsid protein L1 of human papilloma virus
Motevalli et al. Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo
US9738691B2 (en) Truncated L1 protein of human papillomavirus type 58
US9364529B2 (en) Truncated L1 protein of human papillomavirus type 18
US20240000915A1 (en) C-terminally modified human papillomavirus type 11 l1 protein and use thereof
US20170166612A1 (en) Method for enhancing immunogenicity of epitope peptide of hpv antigen, virus-like particle, and method for preparing hpv vaccine
CA2340422C (en) Method for producing yeast expressed hpv types 6 and 16 capsid proteins
IL296578A (en) Immune preparations for the treatment of the corona virus
RU2546243C1 (ru) Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
JP6916115B2 (ja) ＨＰＶＬ２ペプチド／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症用ワクチン
CN109750050B (zh) 重组人乳头瘤病毒45亚型蛋白表达
WO2023275060A1 (en) Sars-cov-2 peptides and proteins with reduced adherence to angiotensin converting enzyme-2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170215

FZDE Discontinued

Effective date: 20180911